Cytokinetics (CYTK) Competitors $33.64 +0.60 (+1.82%) Closing price 04:00 PM EasternExtended Trading$33.62 -0.02 (-0.07%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CYTK vs. SMMT, ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, BPMC, and BBIOShould you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Cytokinetics vs. Its Competitors Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines BridgeBio Pharma Cytokinetics (NASDAQ:CYTK) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk. Does the media prefer CYTK or SMMT? In the previous week, Summit Therapeutics had 9 more articles in the media than Cytokinetics. MarketBeat recorded 12 mentions for Summit Therapeutics and 3 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 1.13 beat Summit Therapeutics' score of 0.75 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CYTK or SMMT more profitable? Summit Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -3,201.47%. Cytokinetics' return on equity of 0.00% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cytokinetics-3,201.47% N/A -43.75% Summit Therapeutics N/A -62.87%-51.61% Do insiders and institutionals hold more shares of CYTK or SMMT? 4.6% of Summit Therapeutics shares are owned by institutional investors. 3.4% of Cytokinetics shares are owned by insiders. Comparatively, 84.9% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has preferable earnings and valuation, CYTK or SMMT? Summit Therapeutics has lower revenue, but higher earnings than Cytokinetics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytokinetics$18.47M217.52-$589.53M-$5.29-6.36Summit Therapeutics$700K22,492.29-$221.32M-$0.34-62.35 Which has more volatility and risk, CYTK or SMMT? Cytokinetics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.06, meaning that its share price is 206% less volatile than the S&P 500. Do analysts prefer CYTK or SMMT? Cytokinetics presently has a consensus price target of $70.92, suggesting a potential upside of 110.83%. Summit Therapeutics has a consensus price target of $34.67, suggesting a potential upside of 63.52%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts plainly believe Cytokinetics is more favorable than Summit Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytokinetics 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.93Summit Therapeutics 2 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.79 SummaryCytokinetics beats Summit Therapeutics on 9 of the 17 factors compared between the two stocks. Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTK vs. The Competition Export to ExcelMetricCytokineticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.02B$2.87B$5.52B$8.85BDividend YieldN/A2.70%5.36%4.13%P/E Ratio-6.3621.1726.3119.76Price / Sales217.52263.83409.02110.15Price / CashN/A41.2925.8827.49Price / Book-29.257.237.915.36Net Income-$589.53M-$55.05M$3.15B$248.34M7 Day Performance0.72%-0.74%0.95%1.25%1 Month Performance8.94%6.27%5.25%5.41%1 Year Performance-38.50%0.19%32.63%18.06% Cytokinetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTKCytokinetics4.2775 of 5 stars$33.64+1.8%$70.92+110.8%-39.0%$4.02B$18.47M-6.36250Positive NewsSMMTSummit Therapeutics2.4827 of 5 stars$20.39-0.8%$35.09+72.1%+172.8%$15.14B$700K-59.97110Analyst UpgradeITCIIntra-Cellular Therapies0.9154 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.902 of 5 stars$20.68-2.3%$39.17+89.4%-17.8%$13.26B$3.12B11.752,682High Trading VolumeRDYDr. Reddy's Laboratories3.0194 of 5 stars$15.31+0.5%$16.95+10.7%-1.4%$12.78B$3.81B23.2027,811Positive NewsASNDAscendis Pharma A/S3.5227 of 5 stars$175.78-0.6%$220.67+25.5%+26.6%$10.75B$393.54M-27.991,017Positive NewsVTRSViatris3.0352 of 5 stars$8.85-0.2%$10.40+17.5%-16.0%$10.39B$14.74B-2.7932,000QGENQiagen3.7434 of 5 stars$46.72-0.1%$47.74+2.2%+20.3%$10.39B$2.00B117.145,765Dividend AnnouncementMRNAModerna4.3613 of 5 stars$25.67-0.9%$46.61+81.6%-76.8%$9.93B$3.14B-2.945,800Trending NewsBPMCBlueprint Medicines1.7425 of 5 stars$128.40+0.2%$128.06-0.3%+18.9%$8.29B$508.82M-51.98640Positive NewsHigh Trading VolumeBBIOBridgeBio Pharma4.7079 of 5 stars$42.17+1.1%$56.67+34.4%+70.5%$8.01B$127.42M-11.95400Analyst ForecastInsider Trade Related Companies and Tools Related Companies Summit Therapeutics Alternatives Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Qiagen Alternatives Moderna Alternatives Blueprint Medicines Alternatives BridgeBio Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYTK) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
